April – June 2024
Net sales: TSEK 0 (1,788).
Other operating revenues: TSEK 416 (1,413).
Profit from financial items: TSEK -7,567 (-6,286).
Earnings per share: SEK -0.38 (-0.32).

January – June 2024
Net sales: TSEK 326 (3,955).
Other operating revenues: TSEK 1,458 (543).
Profit from financial items: TSEK -21,761 (-20,903).
Earnings per share: SEK -1.10 (-1.06).
Cash and cash equivalents: TSEK 83,553 (115,442).

Events during the period
• CombiGene regains the global rights to the epilepsy project CG01 as the termination period of the collaboration and
license agreement between the two companies has expired.
• CombiGene discontinues the preclinical development of the lipodystrophy project CGT2.
• CombiGene’s epilepsy project CG01 has been granted patent in two new countries, Australia and India.
• CombiGene is initiating a collaboration with Västra Hamnen Corporate Finance, which includes assignment analysis, monitoring of news flow and web conferences in connection with CombiGene’s quarterly reports. Further, Västra Hamnen will take over as Certified Adviser from 25 August 2024.
• The 2024 Annual General Meeting resolved, in accordance with the shareholder Orphazyme A/S’s proposal, to re-elect Jonas Ekblom, Peter Nilsson, Per Lundin, Gunilla Lundmark and Malin Almgren, and to elect Marcus Isaksson as a new member.
• Annika Ericsson, currently Director Preclinical Development, will take over the role of Chief Scientific Officer from Karin Agerman, who has decided to leave the company.
• CombiGene enters into a license agreement with Spark Therapeutics for certain intellectual property developed or used by Spark in connection with the previous license agreement for CG01.

Events after the end of the period
• CombiGene and KTH Royal Institute of Technology receive grants from Vinnova totaling SEK 1 million.